TSVT — 2Seventy Bio Share News
0.000.00%
Last trade - 00:00- $265.62m
- $95.24m
- $37.86m
Brief: 2seventy bio Provides Update On KarMMa-9 Study And Previews Anticipated Strong Third Quarter Revenue Performance
U.S. STOCKS ON THE MOVE-Abbott Laboratories, Medtronic, Axon
U.S. STOCKS ON THE MOVE-Abbott Laboratories, Medtronic, Axon
2seventy bio rises on Q2 profit
2Seventy Bio Inc reports results for the quarter ended in June - Earnings Summary
Brief: 2Seventy Bio Q2 Basic EPS USD 0.48
Focus: Pharma aims to deliver personalized cancer therapies more quickly
2seventy bio rises on sale of blood disorder treatment to Novo Nordisk
Brief: 2Seventy Bio Announces Sale Of Hemophilia A Candidate And Megatal In Vivo Gene Editing Technology To Novo Nordisk For Up To $40 Million
EU regulator mandates label updates on CAR-T cancer therapies (updated)
2Seventy Bio Inc reports results for the quarter ended in March - Earnings Summary
2Seventy Bio Inc expected to post a loss of 81 cents a share - Earnings Preview
Brief: 2Seventy Bio, Bristol Myers Squibb Announced FDA Approval For Use Of Suspension Lentiviral Vector For Manufacturing Of Abecma
Brief: U.S. FDA Approves Bristol Myers Squibb And 2seventy bio’s Abecma For Triple-Class Exposed Relapsed Or Refractory Multiple Myeloma After Two Prior Lines Of Therapy
US FDA allows expanded use of Bristol Myers' cell therapy for blood cancer (updated)
U.S. FDA allows expanded use of Bristol Myers' cell therapy
Brief: 2Seventy Bio Board Will Temporarily Comprise Nine Members, Until Dan Lynch Steps Down And Nick Leschly Becomes Chairman
U.S. STOCKS ON THE MOVE-Micron, US hotels, Exxon Mobil
U.S. STOCKS ON THE MOVE-Micron, US hotels, Exxon Mobil